IGFBP2 as a context-dependent regulator of metabolic dysregulation in obesity and type 2 diabetes
IGFBP2 may signal metabolic changes in obesity and diabetes, but human proof is still missing.
This review examines IGFBP2 as a potential translational indicator of metabolic dysregulation in conditions including obesity, insulin resis…
A protein called IGFBP2 might signal metabolic changes in obesity and diabetes, but human proof is still missing.
Narrative review explores miRNA signalling versus conventional RNA therapeutics in metabolic dysfunction-associated steatotic liver disease
Tiny Molecules May Stop Liver Disease Before It Starts
This narrative review examines miRNA signalling as a potential therapeutic approach for metabolic dysfunction-associated steatotic liver dis…
Tiny molecules called microRNAs may one day help stop fatty liver disease from turning into something much more serious.
Observational study maps sex-specific molecular architectures in MASLD using multi-omics profiling.
Why does fatty liver disease look different in men and women?
This primary research study analyzed 211 individuals with MASLD using paired liver-blood multi-omics. It found suppressed hepatic amino acid…
Fatty liver disease follows different biological paths in men and women, driven by distinct fat storage and immune signals that could lead t…
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Narrative review estimates global MASLD prevalence at 38% and notes it surpassed viral hepatitis as China's leading cirrhosis cause.
Review finds MASLD is common globally and now leads cirrhosis in China
This narrative review synthesizes global data on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The authors report a glob…
Metabolic Dysfunction-Associated Steatotic Liver Disease now affects 38% of people globally and is the leading cause of cirrhosis in China.
Dihydromyricetin reduces hepatic lipids and improves metabolic markers in murine MASLD models
A Simple Tea Ingredient Could Help Your Liver
A preclinical systematic review and meta-analysis of 14 controlled murine studies in diet-induced MASLD/NAFLD models found that dihydromyric…
A simple tea ingredient called dihydromyricetin reduced liver fat, improved blood sugar, and lowered cholesterol in mice with fatty liver di…
Systematic review shows PCOS in obese women links to high MASLD and 2–4 fold increased cardiovascular and diabetes risks.
PCOS Is Not Just About Your Ovaries Anymore
This systematic review evaluated the extra-ovarian health impacts of polycystic ovary syndrome (PCOS) in women, with a focus on those with o…
Polycystic ovary syndrome is being rethought as a full-body metabolic condition, and that shift could change how — and by whom — it's treate…
Higher fasting glucose-to-HDL ratio associated with increased MASLD risk in non-diabetic Japanese adults
High Blood Sugar Ratio Signals Liver Trouble Even Without Diabetes
A cross-sectional study of 13,682 non-diabetic Japanese adults found each 1-unit increase in the fasting glucose-to-HDL cholesterol ratio wa…
A specific blood sugar to good cholesterol ratio predicts fatty liver disease in healthy adults without diabetes.
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
New Liver Treatments Show Real Promise in Reversing Scarring
A systematic review and network meta-analysis of 10,119 adult patients with MASLD found pegozafermin, obeticholic acid (OCA), and resmetirom…
For the first time, doctors have clear evidence that new medications can help reverse the dangerous liver scarring caused by common fatty li…
Hyperferritinemia is associated with higher liver-related event incidence in patients with metabolic dysfunction-associated steatotic liver disease.
Is high iron protein in your blood a warning sign for worse liver disease outcomes?
This meta-analysis pooled data from 16 observational studies involving 49,754 patients with metabolic dysfunction-associated steatotic liver…
High iron protein levels in blood nearly double the risk of serious liver events for patients with fatty liver disease, flagging a group nee…
Meta-analysis finds fatty pancreas disease in over half of adults with MASLD
Do you have fatty liver? A new look suggests your pancreas might be fatty too.
A systematic review and meta-analysis of 11 observational studies including 21,438 adults with metabolic dysfunction-associated steatotic li…
If you have fatty liver disease, your pancreas is likely fatty too, with rates reaching over 75% in non-Asian groups and 35% in Asian popula…
PFAS exposure linked to sex-specific steroid hormone disruption in MASLD patients
Could common chemicals in our environment worsen fatty liver disease differently in men and women?
An observational study of 104 patients with biopsy-characterized MASLD found PFAS exposure was associated with sex-specific disruption of st…
Common 'forever chemicals' linked to fatty liver disease affect men and women differently by first disrupting steroid hormones.